An interventional study of Dengzhanxixin Capsule plus Placebo Capsule and Placebo in Diabetes, Hypertension and Hypercholesterolemia, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-25.
Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 417 studies in Diabetes Mellitus with a site in China — 100 open to participants now, 117 under way, 11 of them phase 3. Diabetes Mellitus · China.
Among the 417 studies in Diabetes Mellitus with a site in China, this one is the 127th largest by planned enrollment of the 280 interventional ones that give a count, is one of 36 that started in 2022, is one of 118 with no phase, reaches primary completion later than 3 of the 116 other live ones, and was the 259th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →100 of the 417 studies in Diabetes Mellitus with a site in China are open now. Recruiting first, the newest first:
China Medical University, China · Sites in China
Ages 50–75
CSL Behring · Sites in China
Ages 18+
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
417 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 25 · Phase 3 41 · Phase 4 52
First in 2002; this study’s year is marked. 36 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 165 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 143 across the 280 interventional studies, 605 across the 137 observational. Of the 204 that completed or were terminated, 47 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 417 have an industry lead sponsor. The 10 most frequent:
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
China National Center for Cardiovascular Diseases has 8 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
19 of the studies in Diabetes Mellitus with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06309082First Affiliated Hospital of Wenzhou Medical UniversityAssessing Diabetic Foot Ulcer Microcirculation With High-frequency Contrast Enhanced Ultrasound | 2026-12 |
| NCT05105321Tang YidaCardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP) | 2026-12 |
| NCT07489482Jiangsu HengRui Medicine Co., Ltd.A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection | 2026-12 |
| NCT06959784China-Japan Friendship HospitalAssessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) | 2026-12-31 |
| NCT06958640China-Japan Friendship HospitalDa Qing Offspring Study | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 417 studies in Diabetes Mellitus with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this clinical trial is to evaluate whether the antiplatelet efficacy of the Dengzhanxixin capsule is better than that of placebo in individuals at high-risk for atherosclerotic cardiovascular disease (ASCVD).
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of cardiovascular death, and one out of every ten people aged 35-75 in China is at high risk for ASCVD. Platelet activation is an important mechanism for the development of atherosclerosis. Antiplatelet therapy is important in preventing ASCVD.
Dengzhanxixin capsule is an over-the-counter Chinese traditional medicine; currently, it is mainly used for the adjuvant treatment of ischemic stroke and coronary heart disease. A study of 3143 patients with ischemic stroke found that the addition of Dengzhanshengmai capsules to the standard treatment could further reduce the risk of recurrent stroke and was well tolerated without increased risk of bleeding. Animal experiments also observed that Dengzhanxixin capsules had a clear antiplatelet effect. However, the antiplatelet function of Dengzhanxixin capsules in humans is still unclear. In addition, Dengzhanxixin capsules also have potential anti-inflammatory, lipid-lowering, anticoagulant, and antihypertensive effects.
The main objective of this study is to evaluate the antiplatelet efficacy and safety of Dengzhanxixin capsules in individuals at high-risk for ASCVD. The plan of the study is to recruit 165 subjects and the follow up is to be 10 weeks. This study has been approved by the Ethics Committee of Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following three conditions must be met at the same time:
Meet any of the following conditions:
i) Diabetes
ii) LDL-C ≥ 4.9 mmol/L or TC ≥ 7.2 mmol/L
iii) Hypertension; 1.8 mmol/L ≤ LDL-C \< 2.6 mmol/L or 3.1 mmol/L ≤ TC \< 4.1 mmol/L; 3 risk factors (including smoking, HDL-C \< 1.0 mmol/L, ≥ 45 years for male or ≥ 55 years for female)
iv) Hypertension; 2.6mmol/L ≤ LDL-C \< 4.9mmol/L or 4.1mmol/L ≤ TC \< 7.2mmol/L; with 2 or more risk factors (same risk factors as above)
Exclusion Criteria:
Those who meet any of the following conditions are not eligible:
In addition, subjects will be excluded from the randomization clinic if they have any of the following situations:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dengzhanxixin Capsules plus Placebo Capsules
Drug: Dengzhanxixin Capsule plus Placebo Capsule
Dengzhanxixin Capsules plus Placebo Capsules
Drug: Dengzhanxixin Capsule plus Placebo Capsule
Placebo Capsules
Drug: Placebo
Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily
Placebo, 4 capsules each time, twice daily
Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily
Changes in rate of platelet aggregation
inhibition of adenosine diphosphate (ADP)-induced platelet aggregation as measured by optical aggregometry at week 8.
Time frame: "Day 0", "Week 8"
Changes in rate of platelet aggregation
1. inhibition of arachidonic acid (AA) and collagen (COLL) -induced platelet aggregation measured by optical aggregometry at week 8. 2. inhibition of ADP, AA and COLL -induced platelet aggregation measured by optical aggregometry at week 4. 3. At 4 weeks and 8 weeks from baseline, compare the differences of platelet P2Y12 response units (PRU) and aspirin response units (ARU) 4. At 4 weeks and 8 weeks of treatment, compare the differences of P-selectin.
Time frame: "Day 0","Week 4","Week 8"
Changes in blood pressure
Changes in systolic blood pressure (mmHg) and diastolic blood pressure (mmHg) at 4 and 8 weeks of treatment compared with baseline
Time frame: "Day 0","Week 4","Week 8"
Changes in serum lipid profile
changes in total cholesterol (mg/dL) , low-density lipoprotein cholesterol ester (mg/dL) , high-density lipoprotein cholesterol ester (mg/dL) , triglyceride (mg/dL) and lipoprotein(a) (mg/dL) at 4 and 8 weeks of treatment compared with baseline
Time frame: "Day 0","Week 4","Week 8"
Changes in coagulation profile
changes in prothrombin time (s), activated partial thromboplastin time (s), and thrombin time (s) at 4 and 8 weeks of treatment compared with baseline
Time frame: "Day 0","Week 4","Week 8"
Changes in fibrinogen
changes in fibrinogen (g/L) at 4 and 8 weeks of treatment compared with baseline
Time frame: "Day 0","Week 4","Week 8"
Changes in hs-CRP
changes in high-sensitivity C-reactive protein (mg/dL) at 4 and 8 weeks of treatment compared with baseline
Time frame: "Day 0","Week 4","Week 8"
Changes in IL-6
changes in interleukin-6 (pg/mL) at 4 and 8 weeks of treatment compared with baseline
Time frame: "Day 0","Week 4","Week 8"
Changes in HbA1c(%)
Changes in HbA1c at 8 weeks of treatment compared with baseline
Time frame: "Day 0", "Week 8"
Number of Participants with safety endpoint
2) Liver-relate indicators: 1. ALT ≥ 5 times ULN, or 2. ALT ≥ 3 times ULN + bilirubin ≥ 2 times ULN (3) Kidney-related indicators: a. Serum creatinine increased by ≥50% from baseline, or b. Change in eGFR from baseline (4) Serious adverse events (5) Other adverse events related to the study drug (6) Drug discontinuation due to any reason
Time frame: through study completion, an average of 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Dec 2023, 17 months after the start.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 17 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →